Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical therapy is to minimize symptoms and prevent CHD progression. Acute attacks of stable angina are typically managed with nitrates, while first-line chronic antianginal treatment typically consists of beta blockers, long-acting nitrates, or calcium channel blockers. The branded antianginal drug Ranexa (ranolazine) is used in later lines when initial treatment is unsuccessful. Meanwhile, antiplatelet agents, statins, and ACE inhibitors are typically used to prevent CV events. Using a longitudinal claims data analysis, we demonstrate how stable angina is being treated in the United States and provide insights into what is driving current prescribing practices for newly diagnosed and recently treated patients.
Geography: United States
Real World Data: Longitudinal patient-level claims data analysis
Key Drugs Covered: Beta blockers, calcium channel blockers, nitrates, antiplatelet agents, statins, ACE inhibitors, Ranexa (ranolazine).
Key Analysis Provided: Brand/therapy usage across longitudinal patient sample. Newly diagnosed patient analysis. Treatment initiation and progression. Line of therapy analysis. Combination therapy analysis. Source of business for recently treated patients. Persistency and compliance analysis. Product-level patient flowcharts.
PRODUCT DESCRIPTION: Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.